Shanghai, China, Aug 31,2023./ OBiO Technology (Shanghai) Corp., Ltd. (”OBiO” or the “Company”, Stock code: SH688238) today announced that it entered into a strategic cooperation agreement (the "Agreement") with today announced that it entered into a strategic cooperation agreement with Shanghai Tofflon Science and Technology Co.Ltd.(Short for “Tofflon”, Stock code:SZ300171).

 

According to the agreement, OBiO and Tofflon will cooperate with each other in the field of Cell and Gene Therapy，OBiO With advanced production processes, quality control technologies, manufacturing capabilities, and the ability for large-scale industrialization。And Tofflon provides customized equipment and manufactured consumable materials. Each party will rely on the resources of the other party to empower each other and partnering to serve valued customers，in order to improve their competitive positions.

Guodong Jia，CEO of OBiO，said: “Tofflon's produced equipment and consumable materials are known for their reliability, and their values align closely with ours. The signing of this strategic agreement accelerates cell and gene industrial deployment, this strategic agreement aims to facilitate the better and faster development of the global field of cell and gene therapy.”

 

Xiaodong, Zheng, CEO of Tofflon stated, "OBiO Technology is a leading CRO and CDMO company of cell and gene therapy. We are highly honored to strategically cooperate with OBiO. In future, we will continue to work closely with our own abilities, to promote the development of the industry.”

 

About Shanghai Tofflon Science and Technology Co.Ltd.

Shanghai Tofflon Science and Technology Co. Ltd. (Short for "Tofflon", Stock Code: SZ 300171) was founded in 1993. It is a comprehensive pharmaceutical equipment supplier to provide process support, core equipments, integrated system and pharma engineering for the pharma and biotech industry in the world. Since its foundation, Tofflon has supplied more than 8000 equipments and systems for 2000 pharmaceutical companies across over 40 countries and regions in the world which have been widely applied in the fields of liquid and lyo injectables, chemical API, bioengineering and pharma packaging, etc.

About OBiO Technology

OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH) is a gene and cell therapy-focused CRO and CDMO founded in 2013. In China for global customers, we offer holistic research, development, and manufacturing solutions for vectorology studies, functional genomics, process and analytical development, IND-enabling CMC, clinical and commercial manufacturing. With "enable gene therapy for better lives" as our mission, we are committed to providing high-quality service to global customers, advancing your product from bench to clinic, and bringing benefit to populations around the world. For more information about OBiO Technology, visit www.obio-tech.com.

SOURCE OBiO Technology (Shanghai) Corp., Ltd.